Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More

New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.

September 15, 2017 / 04:04 PM IST

In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.

He said that pharma companies are aware that US generic market is not a one-way street.

According to him new draft pharma policy will reduce risks like generalisation of market.

He said that it is tough to talk about timeline with regards to recovery in pharma space.

Cipla looks good due to no visible overhang, he said.

Close

On DRL front, he said biggest risk stands on Dr Reddy's Laboratories from Duvvada perspective.

Watch accompanying video for more details.
first published: Sep 15, 2017 04:04 pm
Sections